

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL

Lifeline Scientific, Inc. ("Lifeline" or "the Company")

For immediate release

7 January 2008

This announcement does not constitute or form part of an offer, or any solicitation of an offer, for securities and any purchase of or application for shares in the placing should only be made on the basis of information contained in the formal admission document issued in connection with the placing and the admission to AIM.

Lifeline Scientific announces successful completion of IPO

Trading commences today

Addressing the global problem of human donor organ shortage

Lifeline Scientific, a medical technology company primarily focused on commercialising its LifePort® Kidney Transporter, a product designed to address the global challenge of human donor organ shortages, announces the successful completion of its flotation on the AIM Market of the London Stock Exchange. The Company raised a total of £5.4 million from the placing of new common shares with institutional and other investors at a price of 150p per share.

The Company will have a market capitalisation of approximately £23.58 million upon admission and its common shares are expected to commence trading at 08:00 today under the ticker symbol "LSI". Seymour Pierce Limited acted as nominated adviser and broker to the Company. In conjunction with Seymour Pierce Limited, ProSeed Capital Holdings CVA advised the Company on the financing.

Introduction

Lifeline Scientific is a medical technology company that is primarily focused on the commercial launch of its LifePort® Kidney Transporter. LifePort®, marketed through the Company's Organ Recovery Systems business unit, is FDA cleared/ CE marked, clinically validated and has generated over \$9 million in revenues during its pilot introduction to the marketplace.

In comparison with static cold storage, the current standard method for kidney preservation which employs a cooler or cardboard box filled with ice, recent clinical study findings suggest that LifePort® preserved kidneys offered statistically significant advantages. Study findings demonstrated improved patient outcomes including:

- Reduced risk of Delayed Graft Function (DGF);
- Reduced duration of DGF and Primary Non Function; and
- Improved graft survival at 6 months post-transplant.

LifePort® has also been shown to improve the utilization of donated kidneys and increase the organ recovery rate. These benefits along with data reported from other machine preservation studies suggest that reduced overall costs of kidney transplantation may also be achieved with the LifePort®.

LifePort® is thus a new tool that can help increase the number of kidneys being made available for transplant while improving the quality of those organs and potentially lowering transplant related healthcare costs.

LifePort® products for heart, liver, lung and pancreas are also in late stage pre-clinical development.

Lifeline Scientific also operates two subsidiary businesses that leverage the LifePort® technology platform addressing unmet needs in the fields of drug development and cell & tissue transplantation.

Details of the Placing

- The Placing comprised a total of 3,675,074 Placing Shares.
- The Company raised gross proceeds of £5.4 million from the Placing, which will principally be used to fund the full commercial launch and development of LifePort® Kidney Transporter.
- The enlarged issued share capital at admission will be 15,721,340 common shares. In addition, on Admission the Company will have a number of warrants and options in existence which carry the right to the issue of a further 5,749,044 Common Shares in the Company. The Company is at an early stage in its development and should additional funding become available the Company will look to carry out further equity fundraisings at any time following Admission.
- The directors have agreed not to dispose of any of their common shares in the Company prior to the anniversary of admission and, for a period of 12 months following such anniversary, any disposal will be made through Seymour Pierce to preserve an orderly market in the Company's shares. In addition, certain key shareholders have agreed not to dispose of any of their common shares in the Company for a period of six months following Admission.
- Admission and commencement of trading on the London Stock Exchange's AIM market is expected to take place at 08:00 today under the ticker symbol "LSI". The Company is expected to be listed in the Healthcare sector.

David Kravitz, Chief Executive of Lifeline, said:

"Lifeline Scientific's LifePort® Kidney Transporter has been well received in its pilot introduction phase in main transplant centres throughout the world. Initial indications suggest that LifePort® has helped increase the number of transplantable donor kidneys and improved clinical outcomes.

"We are delighted to have successfully completed our IPO and the money raised will enable us to fund the commercial launch of the product in the world's key markets."

Enquiries:

Lifeline Scientific, Inc.
David Kravitz, CEO

Nominated Advisor and Broker
Seymour Pierce +44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs

Investor and Media Communications
Financial Dynamics +44 (0)20 7831 3113
Ben Brewerton / John Dineen

Advisors to the Company
ProSeed Capital Holdings CVA +972 (3) 528 0875
Dror Ben- Asher

The Product

The lead product, LifePort® Kidney Transporter, is a portable machine perfusion device for kidneys. It is FDA approved, CE marked, clinically validated and revenue-generating. The device may potentially replace or augment for most uses the current standard method for kidney preservation, and transport – a cooler or cardboard box filled with ice. Machine-perfusion has been clinically demonstrated to help increase the number of available donor organs by enabling more effective access to different categories of donor (non-heartbeating and expanded criteria donors), improve clinical outcomes and organ utilisation, and potentially reduce overall healthcare cost.

LifePort® Kidney Transporter is already well accepted in the market place. It is currently in pilot introduction phase with 75 key transplant centres worldwide and has generated revenues of approximately \$9m during this period.

Market Opportunity

There is a significant unmet need for donor kidneys. In 2006, there were 17,000 kidney transplants in the US, with a further 72,000 patients on the waiting list. The average wait for a kidney transplant in the US is 3.6 years. Annually, thousands of patients die waiting for a donor kidney. The dramatic supply/demand imbalance is similar for Europe and worldwide.

Further Products

In collaboration with key transplant centres in the US and Europe, other LifePort® systems are in development stage for the preservation and transport of the heart, lung, liver and pancreas.

Use of Proceeds and Growth Strategy

Marketed through the Company's Organ Recovery Systems division, the formal commercial launch of LifePort® is due shortly. Growth will come from increasing the installed base of the equipment, higher utilisation of the equipment and the components required for each individual perfusion, and expanding the customer base geographically. The business model suggests recurring income mostly through consumable sales.

The IPO proceeds will principally be used to fund the commercial launch of LifePort® Kidney Transporter.